Affordable Access

Publisher Website

A Scalable System for Production of Functional Pancreatic Progenitors from Human Embryonic Stem Cells

Public Library of Science
Publication Date
DOI: 10.1371/journal.pone.0037004
  • Research Article
  • Biology
  • Biophysics
  • Biomechanics
  • Cell Mechanics
  • Cell Motility
  • Developmental Biology
  • Morphogenesis
  • Cell Migration
  • Stem Cells
  • Cell Potency
  • Embryonic Stem Cells
  • Stem Cell Lines
  • Cell Differentiation
  • Cell Fate Determination
  • Molecular Cell Biology
  • Extracellular Matrix
  • Extracellular Matrix Adhesions
  • Cell Death
  • Cell Division
  • Cell Growth
  • Cellular Types
  • Medicine
  • Endocrinology
  • Diabetic Endocrinology
  • Diabetes Mellitus Type 1
  • Medicine


Development of a human embryonic stem cell (hESC)-based therapy for type 1 diabetes will require the translation of proof-of-principle concepts into a scalable, controlled, and regulated cell manufacturing process. We have previously demonstrated that hESC can be directed to differentiate into pancreatic progenitors that mature into functional glucose-responsive, insulin-secreting cells in vivo. In this study we describe hESC expansion and banking methods and a suspension-based differentiation system, which together underpin an integrated scalable manufacturing process for producing pancreatic progenitors. This system has been optimized for the CyT49 cell line. Accordingly, qualified large-scale single-cell master and working cGMP cell banks of CyT49 have been generated to provide a virtually unlimited starting resource for manufacturing. Upon thaw from these banks, we expanded CyT49 for two weeks in an adherent culture format that achieves 50–100 fold expansion per week. Undifferentiated CyT49 were then aggregated into clusters in dynamic rotational suspension culture, followed by differentiation en masse for two weeks with a four-stage protocol. Numerous scaled differentiation runs generated reproducible and defined population compositions highly enriched for pancreatic cell lineages, as shown by examining mRNA expression at each stage of differentiation and flow cytometry of the final population. Islet-like tissue containing glucose-responsive, insulin-secreting cells was generated upon implantation into mice. By four- to five-months post-engraftment, mature neo-pancreatic tissue was sufficient to protect against streptozotocin (STZ)-induced hyperglycemia. In summary, we have developed a tractable manufacturing process for the generation of functional pancreatic progenitors from hESC on a scale amenable to clinical entry.

There are no comments yet on this publication. Be the first to share your thoughts.